FBIO (Fortress Biotech) Cyclically Adjusted Revenue per Share: $10.66 (As of Mar. 2026)


FBIO Fortress Biotech Inc FBIO
44 GF Score
Price $3.30
GF Value $1.24
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Fortress Biotech Cyclically Adjusted Revenue per Share?

Fortress Biotech FBIO +0.76% 44 Cyclically Adjusted Revenue per Share is $10.66 as of Mar. 2026. GuruFocus rates FBIO with a GF Score™ of 44/100 and a GF Value™ of $1.24 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Fortress Biotech's adjusted revenue per share for the three months ended in Mar. 2026 was $0.418. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $10.66 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Fortress Biotech's average Cyclically Adjusted Revenue Growth Rate was 2.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 4.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Fortress Biotech was 9.20% per year. The lowest was 0.00% per year. And the median was 2.70% per year.

As of today (2026-07-11), Fortress Biotech's current stock price is $3.295. Fortress Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $10.66. Fortress Biotech's Cyclically Adjusted PS Ratio of today is 0.31.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Fortress Biotech was 9.65. The lowest was 0.12. And the median was 0.78.


Fortress Biotech  (NAS:FBIO) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Fortress Biotech's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3.295/10.66
=0.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Fortress Biotech was 9.65. The lowest was 0.12. And the median was 0.78.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Fortress Biotech Cyclically Adjusted Revenue per Share Related Terms


Fortress Biotech Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Fortress Biotech's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fortress Biotech Cyclically Adjusted Revenue per Share Chart

Fortress Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.49 10.47 10.81 10.28 10.46

Fortress Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.44 10.32 10.44 10.46 10.66

FBIO vs RLYB, INO, SEER: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Fortress Biotech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fortress Biotech Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortress Biotech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Fortress Biotech's Cyclically Adjusted PS Ratio falls into.


FBIO
44GF Score
Fortress Biotech Inc FBIO
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fortress Biotech Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Fortress Biotech's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.418/330.2130*330.2130
=0.418

Current CPI (Mar. 2026) = 330.2130.

Fortress Biotech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.839 241.018 1.149
201609 0.364 241.428 0.498
201612 4.707 241.432 6.438
201703 16.604 243.801 22.489
201706 18.756 244.955 25.284
201709 17.269 246.819 23.104
201712 -41.673 246.524 -55.820
201803 2.082 249.554 2.755
201806 2.357 251.989 3.089
201809 1.731 252.439 2.264
201812 3.128 251.233 4.111
201903 1.523 254.202 1.978
201906 2.582 256.143 3.329
201909 2.578 256.759 3.316
201912 2.798 256.974 3.595
202003 3.052 258.115 3.905
202006 2.069 257.797 2.650
202009 1.868 260.280 2.370
202012 2.584 260.474 3.276
202103 2.150 264.877 2.680
202106 3.305 271.696 4.017
202109 3.888 274.310 4.680
202112 3.278 278.802 3.882
202203 4.161 287.504 4.779
202206 3.192 296.311 3.557
202209 2.772 296.808 3.084
202212 2.715 296.797 3.021
202303 1.830 301.836 2.002
202306 2.357 305.109 2.551
202309 4.634 307.789 4.972
202312 1.855 306.746 1.997
202403 0.760 312.332 0.804
202406 0.813 314.175 0.855
202409 0.743 315.301 0.778
202412 0.581 315.605 0.608
202503 0.497 319.799 0.513
202506 0.550 322.561 0.563
202509 0.533 324.800 0.542
202512 0.529 324.054 0.539
202603 0.418 330.213 0.418

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $10.66 mean?
Fortress Biotech (FBIO) has a Cyclically Adjusted Revenue per Share of $10.66 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Fortress Biotech and its competitors.
Is Fortress Biotech's Cyclically Adjusted Revenue per Share too high?
Fortress Biotech's current Cyclically Adjusted Revenue per Share is $10.66. Overall, Fortress Biotech has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fortress Biotech's Cyclically Adjusted Revenue per Share compare to RLYB and INO?
Fortress Biotech's Cyclically Adjusted Revenue per Share of $10.66 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Fortress Biotech and its competitors. Fortress Biotech's current Cyclically Adjusted Revenue per Share is $10.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fortress Biotech stock overvalued right now?
Based on GuruFocus' analysis, Fortress Biotech (FBIO) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.24, compared to a current price of $3.30 — trading 165.7% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $10.66. Fortress Biotech's overall GF Score™ is 44/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Fortress Biotech (FBIO), the current Cyclically Adjusted Revenue per Share is $10.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fortress Biotech (FBIO) Overvalued in 2026?

Based on GuruFocus' analysis, Fortress Biotech stock appears to be overvalued. The current stock price of $3.30 is trading 165.7% above its estimated GF Value™ of $1.24. GuruFocus considers Fortress Biotech to be Significantly Overvalued.

Key valuation signals for FBIO:

  • Cyclically Adjusted Revenue per Share: $10.66
  • GF Value™: $1.24 vs. price of $3.30 (165.7% above fair value)
  • GF Score™: 44/100 with 7 warning signs

No single metric tells the full story. See the FBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fortress Biotech Business Description

Address 1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
44GF Score

Get the complete analysis for FBIO

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.30
Price
$1.24
GF Value